DAH should be of concern when acute respiratory failure with ground‐glass shadow develops in both lungs during anticoagulation therapy with LMWH.

Respirology Case Reports

Diffuse alveolar hemorrhage (DAH) has a varied etiology, including anticoagulation drugs. There is conflicting evidence whether low molecular weight heparin (LMWH) has a low risk of bleeding complications compared to unfractionated heparin. We report here a case of DAH in a 74‐year‐old woman who was administered enoxaparin, a LMWH, after bilateral total knee arthroplasty. Although congestive heart failure after blood transfusion and fluid infusion could in part be associated with the bleeding, LMWH may be a major cause of DAH since the patient quickly recovered after its cessation. DAH should be of concern when acute respiratory failure with ground‐glass shadow develops in both lungs during anticoagulation therapy with LMWH.

DAH should be of concern when acute respiratory failure with ground‐glass shadow develops in both lungs during anticoagulation therapy with LMWH.

Diffuse alveolar hemorrhage associated with low molecular weight heparin